Angiotensin II receptor blockers (ARBs) (Losartan, valsartan, candesartan, eprosartan, telmisartan)

  • They selectively block AT1 receptors.

  • They have no effect on bradykinin metabolism.

  • They have the potential for more complete inhibition of Ang-2 action compared with ACE inhibitors because there are non-ACE enzymes (cathepsin and chymase) that can convert Ang-1 into Ang-2.

The adverse effects and contraindications

are similar to those described for ACE inhibitors but cough and angioedema are less common than with ACE inhibitors.